The majority of those cancer cells are AR+CXCR2− luminal cancer cells [170], but there are also AR−CXCR2+ neuroendocrine cancer cells, which account for about 0.5% of all tumor cells in low-grade prostate cancer to 20% in metastasis prostate cancer [170]. This evidence concerns the gene AR and neuroendocrine carcinoma.